FINWIRES · TerminalLIVE
FINWIRES

GDI Property Group to Sell Remaining Autoleague Portfolio Assets for AU$42.8 Million

By

GDI Property Group (ASX:GDI) reached deals to sell the remaining five properties in the Autoleague portfolio, owned by GDI No. 46 Property Trust, for about AU$42.8 million, according to a Thursday filing with the Australian bourse.

The company acquired the 17-asset portfolio in February 2020 for AU$98 million and started selling it down in early fiscal 2025. Following the settlement of the last five assets on Aug. 19, investors are expected to receive a final capital return of about AU$0.344 cents per unit, bringing aggregate capital returns to over AU$1.40 per unit.

GDI owns a roughly 47.2% stake in the trust and will receive about AU$12.2 million from the final capital return, as well as disposal and performance fees of about AU$6.2 million, the company said.

Related Articles

Asia

Hanwei Electronics Applies for Hong Kong Listing

Hanwei Electronics (SHE:300007) submitted an application to list on the Hong Kong Exchange, according to a Thursday filing with the Shenzhen bourse.The gas sensor manufacturer plans to use the proceeds to put up research and development facilities, fund investments and acquisitions, expand production bases locally and abroad, boost marketing, and beef up working capital, according to a prospectus submitted to the Hong Kong bourse.

$SHE:300007
Asia

Immutep Reports Survival Benefit Linked to Immune Response in Efti Clinical Trial Analysis

Immutep (ASX:IMM) said a systematic evaluation of five clinical trials of eftilagimod alfa (efti), an antigen-presenting cell (APC) activator, in combination with standard-of-care therapies in late-stage cancer patients showed a significant increase in circulating absolute lymphocyte count (ALC) compared to standard-of-care alone, according to a Thursday Australian bourse filing.The company said increased ALC was significantly associated with improved clinical outcomes, with ALC responders in the efti plus standard-of-care group showing a clinically meaningful median overall survival improvement of 7.7 months compared to ALC non-responders, with no corresponding association observed in the standard-of-care alone group."The findings link the immune-activating effect of efti measured in patients' blood with meaningful and significant survival improvements observed in previous clinical trials," said Immutep's Chief Scientific Officer, Frederic Triebel, adding that the studies highlighted a key connection with efti's mechanism of action and clinical efficacy.The company's shares fell 2% in recent Thursday trade.

$ASX:IMM
Asia

Tianyuan DIC Chair Released From Detention; Shares Jump 7%

Shenzhen Tianyuan DIC Information Technology (SHE:300047) said Chair Chen You was released from residential detention.Chen was originally detained by the Leping City Supervisory Commission in Jiangxi, China, in December 2025, according to a Thursday filing with the Shenzhen bourse.Chen will resume his normal duties.Shares of the information technology company rose 7% in recent trade.

$SHE:300047